Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
After nutritional adjustments and support, symptoms improved significantly
At present, the primary approach to treat patients with CCA remains rooted in surgical interventions, and the prognosis for patients ineligible for surgery is poor (103)
Structure's GLP-1 Pill Could Be Big, But Trial Results Will Confirm Shares of Structure Therapeutics (NASDAQ: GPCR) have far outperformed both of the companies above in the last year, rising by over 150% during that time as investors have grown enthusiastic about aleniglipron, the firm's GLP-1 agonist candidate
:max_bytes(150000):strip_icc()/health-GettyImages-1487915363-80745904e3404eef8fde4af76e6fa6f0.jpg)
J.YangY
US$ 25.92
US$ 27.38
US$ 24.00
US$ 29.15
US$ 23.24
US$ 24.16
US$ 25.63
US$ 28.51
US$ 20.80
